دورية أكاديمية
Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations.
| العنوان: | Immune checkpoint inhibitors in women with gynecologic cancers: Practical considerations. |
|---|---|
| المؤلفون: | Kurnit KC; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, United States. Electronic address: kkurnit@bsd.uchicago.edu., Reid P; Department of Medicine, Section of Rheumatology, The University of Chicago, Chicago, IL, United States., Moroney JW; Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, The University of Chicago, Chicago, IL, United States., Fleming GF; Department of Medicine, Section of Hematology-Oncology, The University of Chicago, Chicago, IL, United States. |
| المصدر: | Gynecologic oncology [Gynecol Oncol] 2020 Sep; Vol. 158 (3), pp. 531-537. Date of Electronic Publication: 2020 Jul 05. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: New York, Academic Press. |
| مواضيع طبية MeSH: | Genital Neoplasms, Female/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use ; B7-H1 Antigen/antagonists & inhibitors ; B7-H1 Antigen/biosynthesis ; B7-H1 Antigen/immunology ; Female ; Genital Neoplasms, Female/immunology ; Humans ; Immune Checkpoint Inhibitors/adverse effects |
| مستخلص: | Immune checkpoint inhibitors are an exciting new class of cancer therapeutics. Recently, a PD-1 inhibitor has been approved by the Food and Drug Administration for several indications that are relevant to patients with gynecologic malignancies. In this review, we explore the clinical considerations for the use of checkpoint inhibitor therapy in this population. Specifically, we will discuss the approved indications, recommended dosing, clinical monitoring while on treatment, common adverse events, and treatment of adverse events should they arise. Additionally, we will review mechanisms of resistance and other challenges associated with the use of checkpoint inhibitors. We will conclude with a discussion of possible future directions for immunotherapy in women with gynecologic cancers. Competing Interests: Disclosures KCK reports travel support from GOG-Foundation, served on an advisory board for GOG-Foundation regarding LEAP Therapeutics, outside the submitted work. GFF reports personal fees from Up To Date, non-financial support from Corcept, personal fees from GSK, personal fees from ASCO, personal fees from Vaniam Group, unpaid membership on clinical trial steering committee from AbbVie, and is an Institutional PI of Industry Trials from Merck, Syndax, 47 Inc., Sanofi, Astex, EMD Sereno, Roche/Genentech, Syros, Tesaro, Iovance, Sanofi, Sermonix, Incyte, Compugen, Abbvie, and Eisai, outside the submitted work. PR and JWM report no disclosures. (Copyright © 2020 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Checkpoint inhibitors; Gynecologic cancers; Immunotherapy |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Humanized) 0 (B7-H1 Antigen) 0 (CD274 protein, human) 0 (Immune Checkpoint Inhibitors) DPT0O3T46P (pembrolizumab) |
| تواريخ الأحداث: | Date Created: 20200710 Date Completed: 20210415 Latest Revision: 20210415 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.ygyno.2020.06.499 |
| PMID: | 32641238 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder كن أول من يترك تعليقا!